Quick Answer
Propanc Biopharma, Inc. reported Earnings Per Share Diluted of $14.85 (loss) per share for the year ending 2025.
- Propanc Biopharma, Inc. showed an increase of +99.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Propanc Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $2.13 (loss) per share | Q4 2022: $0.53 (loss) per share | Q1 2023: $0.42 (loss) per share | Q3 2023: $0.04 (loss) per share | Q4 2023: $1,559.55 (loss) per share | Q1 2024: $545.79 (loss) per share | Q3 2024: $35.97 (loss) per share | Q4 2024: $32.23 (loss) per share | Q1 2025: $12.50 (loss) per share | Q3 2025: $0.39 (loss) per share | Q4 2025: $0.30 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Propanc Biopharma, Inc.'s Earnings Per Share Diluted has grown by 69.8%.
- Historical annual values: Fiscal year 2025: $14.85 (loss) per share | Fiscal year 2024: $1,420.53 (loss) per share | Fiscal year 2023: $1.80 (loss) per share | Fiscal year 2022: $49.23 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: